ImmunoPrecise Antibodies Ltd.
IPA.V
Get informed when a big investor buys or sells
+ FollowMarket Cap$74.77M
Close$
Share Statistics
| Market cap | $74.77 Million |
|---|---|
| Enterprise Value | $65.09 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $- |
| Beta | 0.3 |
| Outstanding Shares | - |
Return
| Return on Equity | -81.55% |
|---|---|
| Return on Assets | -52.72% |
| Return on Invested Capital | -68.91% |
Valuation & Multiples
| P/E Ratio | -5.84 |
|---|---|
| PEG | 7.12 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 3.54 |
| Enterprise Value to EBIT | -5.22 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | 0.3 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About ImmunoPrecise Antibodies Ltd
2,021 employees
CEO: Jennifer Lynne Bath IPA is an innovation-driven, technology platform company that supports its pharmaceutical and biotechnology company partners in their quest to discover and develop novel, therapeutic antibodies against all classes of disease targets. The...